Clinical Trial Update: Safety and Pharmacokinetics of RTH258 in Subjects With Age-Related Macular Degeneration [Phase 2]

View source ↗

Summary

This Phase 2 trial update summarizes safety and pharmacokinetics data for RTH258 (brolucizumab) in subjects with neovascular age-related macular degeneration. T…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration
• Neovascular Age-related Macular Degeneration

Drugs mentioned

• RTH258 (brolucizumab) (brolucizumab)

Snippet

Sponsor: Alcon Research | Conditions: Neovascular Age-Related Macular Degeneration | Phase 2 | Status: COMPLETED | Results posted: 2017-09-29